{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Adjuvant \u03b1DC1 Vaccination with Chemokine Modulation after CRS/HIPEC"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This single-institution phase II trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "enrolled patients with appendiceal cancer, colorectal cancer, or peritoneal mesothelioma at the University of Pittsburgh. Eligibility included histologically proven peritoneal metastases and the ability to undergo plasmapheresis."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received intranodal and intradermal injections of autologous tumor-loaded \u03b1DC1 vaccine and CKM, consisting of celecoxib, interferon (IFN)-\u03b1, and rintatolimod."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the safety and efficacy of adjuvant \u03b1DC1 vaccination with chemokine modulation (CKM) following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was progression-free survival (PFS), measured over a median follow-up period."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Forty-six patients were analysed, with 24 appendiceal, 20 colorectal, and 2 mesothelioma cases."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Forty-six patients were analysed"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Median PFS for appendiceal cancer was 50.4, 34.2, and 8.9 months for grades 1, 2, and 3, respectively, and 20.5 and 8.9 months for moderately and poorly differentiated colorectal tumors."
      },
      "Harms": {
        "score": 1,
        "evidence": "The regimen was well tolerated, with common adverse events being mild flu-like symptoms. Six patients experienced grades 3\u20135 adverse events, including lymphocyte count decrease and gastrointestinal bleed."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under NCT02151448."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding was provided by institutional sources."
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}